Although Elagolix hasn’t attracted as much attention from investors as Bardoxolone and ABT’s HCV pipeline, management considers it one of the most important drugs in ABT’s (soon to be Abbvie’s) late-stage pipeline.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”